Clinical Trials Logo

Clinical Trial Summary

The Ovulation Double Check test is a Class I, 510K exempt medical device. It is manufactured and packaged in an FDA-registered and cGMP compliant facility. This device measures the level of Pregnanediol (PdG), the major urine metabolite of progesterone, in the urine of women. PdG has been shown to increase significantly after ovulation has occurred. This test will be used in a home setting as a point-of-care device, providing couples additional information about menstrual cycling and possible fertile periods. The investigators have successfully developed prototype devices that can accurately measure PdG in urine. Now the investigators need to supply these prototype devices to end users to verify the assay is working correctly and determine if the device was designed properly in order for home users to 1) use the test properly, 2) read the test results properly, and 3) interpret the results correctly.


Clinical Trial Description

Lack of or insufficient ovulatory events is the primary cause of infertility worldwide and with 12% of couples within the US being diagnosed with infertility each year (according to the CDC), thus being able to confirm ovulation is an essential component of infertility evaluations in women. The gold standards for confirming ovulation include transvaginal ultrasounds and serum progesterone blood draws. Both of these techniques are too invasive, too expensive, and/or inaccessible to most women. Therefore a non-invasive, inexpensive, home-based testing system to confirm ovulation is desired. Several recent studies have identified urinary pregnanediol levels as an accurate way to confirm ovulation. However, until now, urine pregnanediol levels were always measured via a lab setting. Here the investigators describe the development of a urine pregnanediol (PDG) rapid test and its use at confirming ovulation in a home environment. Study Protocol One hundred and ninety six women were recruited to take part in a prospective, blinded cohort home environment study. The study protocol was approved by the Ethics Committee at Solutions IRB. Detailed information about the study was provided to each volunteer, and informed consent was obtained prior the study commencement. Inclusion criteria were non-pregnant women residing within the United States, aged 18- 45, and not currently on hormonal birth control. Importantly, women were not excluding due to average cycle length, weight (BMI), breastfeeding status, poly-cyctic ovarian syndrome (PCOS) or any other cause of infertility or lifestyle factor. Participants were asked to predict ovulation by monitoring changes in cervical mucus and/or tracking luteinizing hormone (LH) via home test kits. Participants were asked to self-report their peak fertility day, which was defined as the first LH surge day and/or day of peak cervical mucus (stretchy and eggwhite in consistence). Participants collected first morning urine as various times during their cycle, including, prior to, during, and after peak fertility signs were observed. Participants were provided PDG rapid response test strips and self-administered the tests and recorded the results. Test results were reported back the investigators via a log sheet. Log sheets recorded testing date, day of cycle, date of peak fertility (if known), personal assessment of results (positive result vs negative result) and a place to tape the completed test strip. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03924440
Study type Observational
Source MFB Fertility
Contact
Status Completed
Phase
Start date October 1, 2016
Completion date December 31, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT02264847 - Human Chorionic Gonadotrophin & Trigger Phase 3
Recruiting NCT04979377 - Prevalence of Hyperandrogenism in Type 1 Diabetes
Not yet recruiting NCT06292806 - Inhibin B/AFC Ratio for Ovarian Response
Completed NCT03309176 - "Stair Step Study" Phase 4
Not yet recruiting NCT03989024 - Pulsatile Gonadotropin-releasing Hormone for Infertility in Non-obese Patients With Polycystic Ovary Syndrome Phase 4
Completed NCT04942457 - Feasibility and Safety of Fasting in Fertility Treatment N/A
Not yet recruiting NCT02940535 - Low Dose GnRHa Early Luteal Phase Down Regulation Versus GnRHa Ultra-short Protocol for Poor Ovarian Response N/A
Recruiting NCT04075149 - Does Treatment of Androgen Excess Using Spironolactone Improve Ovulatory Rates in Girls With Androgen Excess? Early Phase 1
Recruiting NCT05211583 - Serial Progesterone Level Measurements During the Menstrual Cycle in Subfertile Women
Withdrawn NCT04002635 - Letrozole for Frozen Embryo Transfer (FET) in Patients With Polycystic Ovary Syndrome (PCOS) Phase 4
Completed NCT03924453 - Usability Study of the Pearl Fertility Tracking Device
Completed NCT04210765 - Incremental Clomiphene Citrate Doses in Successive Cycles and FSH, LH and Steroid Hormone Levels Phase 4
Completed NCT01999569 - The Role of Estrogen in Luteinizing Hormone Surge and Ovulation Phase 4